Welcome to our dedicated page for Cipla 144 Gdr news (Ticker: CPLFY), a resource for investors and traders seeking the latest updates and insights on Cipla 144 Gdr stock.
Cipla Limited (CPLFY) reports pharmaceutical developments centered on its U.S. portfolio, including USFDA approvals, ANDA and NDA pathways, and launches of generic and complex products. Recurring updates cover medicines such as Liraglutide Injection, Leuprolide Acetate Injection Depot, Lenalidomide capsules, Difluprednate Ophthalmic Emulsion, and Albuterol Sulfate Inhalation Aerosol.
The company’s news also includes manufacturing and capacity actions for respiratory products in the United States, quality and recall communications, and collaborations through subsidiaries and joint ventures focused on cell therapy and biosimilars. Investor-facing updates describe corporate presentations and strategic priorities in pharmaceutical development, commercialization, and U.S. market access.
Cipla Limited has received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for the 20 mg Sumatriptan Nasal Spray. This product is a generic version of GlaxoSmithKline's Imitrex® Nasal Spray, indicated for the acute treatment of migraines in adults. According to IQVIA, the U.S. sales of Imitrex Nasal Spray and its generics reached approximately $53.3 million in the year ending December 2020. Cipla aims to leverage this approval to expand its presence in the migraine treatment market.
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) announced on September 28, 2020, that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules in 120mg and 240mg doses. This product is a generic version of Biogen IDEC's Tecfidera®, which saw US sales of approximately $3.8 billion in the 12 months ending July 2020. The generic drug is indicated for treating relapsing forms of multiple sclerosis and is available for shipping immediately, supported by Co-Pay Assistance.
Cipla Limited, along with its partner Stempeutics Research, has received regulatory approval from the Drug Controller General of India for Stempeucel®, the first allogeneic cell therapy approved for treating Critical Limb Ischemia (CLI) due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. This groundbreaking therapy can produce over one million doses from a single set of master cell banks, ensuring affordability and consistent quality. The global market for CLI treatment is projected to reach USD 5,390 million by 2025, growing at a CAGR of 8.1%.